Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Dow
AstraZeneca
Johnson and Johnson
McKinsey
Moodys

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

STAXYN Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Staxyn, and what generic alternatives are available?

Staxyn is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in thirty-seven countries.

The generic ingredient in STAXYN is vardenafil hydrochloride. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the vardenafil hydrochloride profile page.

Drug patent expirations by year for STAXYN
Drug Prices for STAXYN

See drug prices for STAXYN

Drug Sales Revenue Trends for STAXYN

See drug sales revenues for STAXYN

Recent Litigation for STAXYN

Identify potential future generic entrants

District Court Litigation
Case NameDate
Bayer Pharma AG v. Macleods Pharmaceuticals Ltd.2015-06-05
Bayer Pharma AG v. Par Pharmaceutical Inc.2013-05-14
Bayer Pharma AG v. Watson Laboratories, Inc.2012-04-25

See all STAXYN litigation

Pharmacology for STAXYN
Paragraph IV (Patent) Challenges for STAXYN
Tradename Dosage Ingredient NDA Submissiondate
STAXYN TABLET, ORALLY DISINTEGRATING;ORAL vardenafil hydrochloride 200179 2011-12-22

US Patents and Regulatory Information for STAXYN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare STAXYN vardenafil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 200179-001 Jun 17, 2010 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for STAXYN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare STAXYN vardenafil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 200179-001 Jun 17, 2010   Start Trial   Start Trial
Bayer Hlthcare STAXYN vardenafil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 200179-001 Jun 17, 2010   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Medtronic
Merck
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.